Lysosomal Acid Lipase (LAL) Deficiency Registry
Study Identifier:
ALX-LALD-501
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
Date
May 2013 - Aug 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A
Requirements Information
Sex
Female & Male
Age
N/A
Study Details
Medical Condition
- Unmapped
Study Drug
Date
May 2013 - Aug 2029
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A years
Requirements Information
Protocol Summary
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Trial Locations
Location
Status
Location
Clinical Trial Site
Phoenix, Arizona, United States, 85016
Status
Recruiting
Location
Clinical Trial Site
Stanford, California, United States, 94305
Status
Recruiting
Location
Clinical Trial Site
Miramar, Florida, United States, 33025
Status
Recruiting
Location
Clinical Trial Site
Orlando, Florida, United States, 32806
Status
Recruiting
Location
Clinical Trial Site
Atlanta, Georgia, United States, 30322
Status
Recruiting
Location
Clinical Trial Site
Chicago, Illinois, United States, 60611
Status
Recruiting